Investor Relations

Print Print page     Email Email page

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as dengue and influenza. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Mar 26, 2014
Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin

Feb 25, 2014
United Therapeutics Corporation Reports 2013 Fourth Quarter and Annual Financial Results

more »


Jun 2, 2014
Jefferies 2014 Global Healthcare Conference

more »